VOYA Investment Management
BBIO icon

VOYA Investment Management’s BridgeBio Pharma BBIO Stock Holding History

VOYA Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Sell
41,586
-497,394
-92% -$34.8M ﹤0.01% 1061
2026
Q1 		$40M Sell
538,980
-44,381
-8% -$3.22M 0.04% 327
2025
Q4 		$44.6M Buy
583,361
+109,865
+23% +$7.21M 0.04% 324
2025
Q3 		$24.6M Buy
473,496
+4,776
+1% +$233K 0.02% 452
2025
Q2 		$20.2M Buy
468,720
+388,146
+482% +$14.1M 0.02% 529
2025
Q1 		$2.79M Buy
80,574
+9,061
+13% +$306K ﹤0.01% 1171
2024
Q4 		$1.96M Sell
71,513
-3,436
-5% -$88.8K ﹤0.01% 1297
2024
Q3 		$1.91M Sell
74,949
-15,815
-17% -$415K ﹤0.01% 1352
2024
Q2 		$2.3M Sell
90,764
-77,212
-46% -$2.11M ﹤0.01% 1275
2024
Q1 		$5.19M Sell
167,976
-25,063
-13% -$852K 0.01% 983
2023
Q4 		$7.79M Buy
193,039
+117,398
+155% +$3.53M 0.01% 837
2023
Q3 		$1.99M Buy
75,641
+29,378
+64% +$834K ﹤0.01% 1335
2023
Q2 		$796K Sell
46,263
-90,680
-66% -$1.36M ﹤0.01% 1812
2023
Q1 		$2.27M Buy
136,943
+95,365
+229% +$1.11M ﹤0.01% 1306
2022
Q4 		$317K Hold
41,578
– – ﹤0.01% 2301
2022
Q3 		$413K Hold
41,578
– – ﹤0.01% 2148
2022
Q2 		$378K Hold
41,578
– – ﹤0.01% 2010
2022
Q1 		$422K Hold
41,578
– – ﹤0.01% 2006
2021
Q4 		$694K Sell
41,578
-482
-1% -$20.4K ﹤0.01% 1800
2021
Q3 		$1.97M Sell
42,060
-319
-0.8% -$17.1K ﹤0.01% 1182
2021
Q2 		$2.58M Buy
42,379
+1,101
+3% +$62.9K 0.01% 1092
2021
Q1 		$2.54M Buy
41,278
+9,590
+30% +$627K 0.01% 1068
2020
Q4 		$2.25M Buy
31,688
+6,646
+27% +$321K ﹤0.01% 1086
2020
Q3 		$940K Sell
25,042
-675
-3% -$21.2K ﹤0.01% 1320
2020
Q2 		$839K Sell
25,717
-11,321
-31% -$345K ﹤0.01% 1360
2020
Q1 		$1.07M Buy
37,038
+26,199
+242% +$812K ﹤0.01% 1192
2019
Q4 		$380K Buy
+10,839
New +$300K ﹤0.01% 2039

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

VOYA Investment Management's BBIO Position: Q2 2026 in Review

VOYA Investment Management reduced its BridgeBio Pharma (BBIO) stake by 92% in Q2 2026, selling an estimated $34.8M and leaving 41,586 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

VOYA Investment Management first reported a position in BBIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $44.6M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • VOYA Investment Management held 41,586 shares of BridgeBio Pharma worth $3.1M as of Q2 2026.
  • VOYA Investment Management sold 497,394 BridgeBio Pharma shares in Q2 2026, an estimated $34.8M.
  • BridgeBio Pharma made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1061 holding.
  • VOYA Investment Management first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 27 quarters since.
  • VOYA Investment Management's BridgeBio Pharma position peaked at $44.6M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.